B
Benoit Cardinal-David
Researcher at Northwestern University
Publications - 11
Citations - 495
Benoit Cardinal-David is an academic researcher from Northwestern University. The author has contributed to research in topics: Enantioselective synthesis & Catalysis. The author has an hindex of 4, co-authored 11 publications receiving 458 citations. Previous affiliations of Benoit Cardinal-David include Northwest University (United States).
Papers
More filters
Journal ArticleDOI
Cooperative N-heterocyclic carbene/Lewis acid catalysis for highly stereoselective annulation reactions with homoenolates.
TL;DR: A new approach that takes advantage of N-heterocyclic carbene/Lewis acid cooperative catalysis provides access to cis-1,3,4-trisubstituted cyclopentenes from enals and chalcone derivatives with high levels of diastereoselectivities and enantioselectivity.
Journal ArticleDOI
Lewis Acid Activated Synthesis of Highly Substituted Cyclopentanes by the N-Heterocyclic Carbene Catalyzed Addition of Homoenolate Equivalents to Unsaturated Ketoesters†
TL;DR: The use of a Lewis acid is reported as an essential component for an NHC-catalyzed annulation of enals with a new class of electrophiles that fail as competent substrates when only NHCs are used.
Journal ArticleDOI
NHC-catalyzed/titanium(IV)-mediated highly diastereo- and enantioselective dimerization of enals
TL;DR: An NHC-catalyzed, diastereo- and enantioselective dimerization of enals has been developed and the use of Ti(Oi-Pr)(4) is a key element for the reactivity and selectivity of this process.
Patent
Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
Benoit Cardinal-David,Chan Vincent S,Dempah Kassibla E,Brian P. Enright,Henry Rodger F,Raimundo Ho,Ye Huang,Alexander D Huters,Klix Russell C,Krabbe Scott W,Kym Philip R,Lao Yanbin,Xiaochun Lou,Sean E. Mackey,Mark A. Matulenko,Peter T. Mayer,Miller Christopher P,James P. Stambuli,Eric A. Voight,Zhi Wang,Geoff G. Z. Zhang,Stella Valentino J +21 more
TL;DR: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions, and (c) methods of treating Parkinson's disease and associated conditions as mentioned in this paper.
Journal ArticleDOI
Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.
Alexander D Huters,James P. Stambuli,Russell C. Klix,Mark A. Matulenko,Vincent S. Chan,Justin A. Simanis,David R. Hill,Rajarathnam E. Reddy,Timothy B. Towne,John R. Bellettini,Brian J. Kotecki,Benoit Cardinal-David,Jianguo Ji,Eric A. Voight,Minshan Shou,Selvakumar Balaraman,Abhishek Ashok,Soma Ghosh +17 more
TL;DR: In this article, the authors describe asymmetric syntheses of Foslevodopa (FLD) and Foscarbidopa (FCD) drug substances and their manufacture at pilot scale.